This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thomas J. DesRosier (Photo: Business Wire)

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that Thomas J. DesRosier will be joining the Company as Senior Vice President, Chief Legal Officer and Secretary. Mr. DesRosier is currently Senior Vice President, General Counsel North America of Sanofi, a position he assumed following the acquisition by Sanofi of Genzyme Corporation in 2011 where he served as Genzyme’s Senior Vice President, Chief Legal Officer. Mr. DesRosier will report to Cubist CEO Mike Bonney.
Thomas J. DesRosier (Photo: Business Wire)

Thomas J. DesRosier (Photo: Business Wire)

“Tom is a senior biotech leader who brings an outstanding mix of vision, global experience, and strategic thinking to Cubist,” said Mike Bonney. “He is a strong manager who has helped build large and successful global legal teams at a number of biotech and pharmaceutical companies. As we continue to execute against our Building Blocks of Growth goals, I am delighted that he will be here to help us with our exciting next chapter at Cubist.”

Mr. DesRosier brings over 30 years of global biotechnology and pharmaceutical industry experience to Cubist. Prior to his 12 year tenure at Genzyme, Mr. DesRosier held a number of senior legal positions at Wyeth Pharmaceuticals, Genetics Institute, and E.I. DuPont de Nemours. Mr. DesRosier received his J.D. from Wake Forest University School of Law and his Bachelor of Arts in Chemistry from the University of Vermont.

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s web site at

Photos/Multimedia Gallery Available:

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.63 0.65%
FB $101.23 -2.70%
GOOG $676.14 -1.10%
TSLA $154.06 -5.30%
YHOO $27.30 -2.40%


Chart of I:DJI
DOW 15,935.96 -269.01 -1.66%
S&P 500 1,848.75 -31.30 -1.66%
NASDAQ 4,269.3630 -93.7810 -2.15%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs